New Asthma Diagnosis Codes or Short-Acting β₂ Agonist Prescriptions After Histoplasmosis Among Patients With Commercial Health Insurance, United States, 2018-2023.

ABSTRACT:

Background

Although several fungal infections have been linked to asthma development, the relationship between histoplasmosis and asthma development has not been fully described.

Objectives

To assess the incidence of new asthma diagnosis codes or short-acting β₂ agonist (SABA) prescription in the year following histoplasmosis diagnosis and identify potentially related factors.

Methods

We used a large health insurance claims database to identify patients with histoplasmosis with and without an asthma diagnosis code or a short-acting β₂ agonist prescription in the year after diagnosis.

Results

Among 1819 patients diagnosed with histoplasmosis, 252 (13.9%) received a new asthma diagnosis or SABA prescription in the subsequent year, more than

SUBMITTER: Hennessee I 

PROVIDER: S-EPMC12666392 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature